Fibronectin Fibers Progressively Lose Their Tension in Invasive Human Breast Carcinoma while Being Tensed in DCIS and Healthy Breast Tissue
Advanced Science · 2025
DOI: 10.1002/advs.202404351 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Arnaud Miéville und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Applied Mechanobiology, Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zürich, Zürich, Switzerl…. Hauptthemen laut MEDLINE: Fibronectins, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Breast. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, ETH Zürich and ETHeart Initiative of ETH Zürich.
Abstract (Originalsprache)
Extracellular matrix (ECM) remodeling plays critical roles in cancer progression and involves alterations in its composition and biophysical properties. Aggressiveness and malignancy of solid tumors are strongly correlated with tissue stiffening, mainly due to upregulated ECM production and cross‐linking. However, nothing is known about the tensional alterations that occur at the single‐fiber level during tumorigenesis in humans. The well‐validated peptide tension probe (FnBPA5) now reveals that Fibronectin fibers lose their tension as invasive tumors progress while they are stretched in healthy human breast tissue stroma and in ductal carcinoma in situ (DCIS), the non‐invasive precursor of breast cancer. In invasive carcinomas, cancer cells, cancer‐associated fibroblasts (CAFs) and infiltrating immune cells (cytotoxic T cells and regulatory T cells), are predominantly located in proximity to untensed Fibronectin fibers. This is significant, as Fibronectin fiber stretching can mechano‐regulate the reciprocal cell‐ECM crosstalk and the bioavailability of ECM‐bound molecules. Not only tissue stiffening, but also the accumulation of untensed Fibronectin fibers may serve as a mechanical biomarker that correlates with tumor grade. Loss of Fibronectin fiber tension may play a central role in regulating tumor invasiveness. This suggests that physically altered ECM fibers can be exploited for stroma‐targeted drug delivery and immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Applied Mechanobiology, Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zürich, Zürich, Switzerland.
- Breast Center, Department of Gynecology, Kantonsspital Baden, Baden, Switzerland.
- Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
- Institute of Translational Medicine, Department of Health Sciences and Technology, ETH Zürich, Zürich, Switzerland.
- Institute of Pathology, Kantonsspital Baden, Baden, Switzerland.
ORCID-Profile: Arnaud Miéville, Viola Vogel
Förderung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- ETH Zürich and ETHeart Initiative of ETH Zürich
Zitieren
APA
Miéville, A., Fonta, C. M., Leo, C., Christe, L., Goldhahn, J., Singer, G., & Vogel, V. (2025). Fibronectin Fibers Progressively Lose Their Tension in Invasive Human Breast Carcinoma while Being Tensed in DCIS and Healthy Breast Tissue. Advanced Science. https://doi.org/10.1002/advs.202404351
Vancouver
Miéville A, Fonta CM, Leo C, Christe L, Goldhahn J, Singer G, et al. Fibronectin Fibers Progressively Lose Their Tension in Invasive Human Breast Carcinoma while Being Tensed in DCIS and Healthy Breast Tissue. Advanced Science. 2025. doi:10.1002/advs.202404351
BibTeX
@article{Miville2025,
author = {Miéville, Arnaud and Fonta, Charlotte M and Leo, Cornelia and Christe, Lucine and Goldhahn, Jörg and Singer, Gad and Vogel, Viola},
title = {Fibronectin Fibers Progressively Lose Their Tension in Invasive Human Breast Carcinoma while Being Tensed in DCIS and Healthy Breast Tissue},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202404351}
}
EUVIMED